Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Ligand Pharmaceuticals Inc (NASDAQ:LGND)

115.78
Delayed Data
As of Sep 23
 -2.38 / -2.01%
Today’s Change
79.66
Today|||52-Week Range
139.79
+6.79%
Year-to-Date
Ligand Inks CNS License Agreement with Seelos Therapeutics
Sep 23 / Zacks.com - Paid Partner Content
Epizyme Receives Milestone from Glaxo for Lymphoma Drug
Sep 16 / Zacks.com - Paid Partner Content
Teva Reports Positive Phase III Tardive Dyskinesia Data
Sep 23 / Zacks.com - Paid Partner Content
Roche Ocrevus Positive in Phase III Multiple Sclerosis Trials
Sep 15 / Zacks.com - Paid Partner Content
5 Stocks With Amazon-Like Growth Potential
Sep 22 / MotleyFool.com - Paid Partner Content
Shire's Immunodeficiency Treatment Cuvitru Gets FDA Approval
Sep 15 / Zacks.com - Paid Partner Content
Ligand (LGND) Inks Deal with TeneoBio for OmniAb Technology
Sep 19 / Zacks.com - Paid Partner Content
Ligand (LGND) Commences Phase II Type II Diabetes Study
Sep 14 / Zacks.com - Paid Partner Content
Novartis Reports Positive Phase II Data on Migraine Drug
Sep 16 / Zacks.com - Paid Partner Content
5 Biotech Stocks That Are Broker Favorites
Sep 13 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close118.16
Today’s open117.71
Day’s range115.72 - 118.04
Volume192,613
Average volume (3 months)380,767
Market cap$2.4B
Dividend yield--
Data as of 3:59pm ET, 09/23/2016

Growth & Valuation

Earnings growth (last year)+2,064.46%
Earnings growth (this year)+2.30%
Earnings growth (next 5 years)+53.14%
Revenue growth (last year)+11.43%
P/E ratio10.6
Price/Sales32.00
Price/Book7.59

Competitors

 Today’s
change
Today’s
% change
IRWDIronwood Pharmaceuti...-0.15-0.95%
PBHPrestige Brands Hold...+0.46+0.95%
PBYIPuma Biotechnology I...+2.10+3.18%
AGIOAgios Pharmaceutical...0.000.00%
Data as of 4:02pm ET, 09/23/2016

Financials

Next reporting dateOctober 31, 2016
EPS forecast (this quarter)$0.64
Annual revenue (last year)$71.9M
Annual profit (last year)$257.3M
Net profit margin357.80%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
John L. Higgins
President &
Chief Operating Officer
Matthew W. Foehr
Corporate headquarters
La Jolla, California

Forecasts

Search for Jobs